FRM
VIR icon

Fox Run Management’s Vir Biotechnology VIR Stock Holding History

Fox Run Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,089
Closed -$299K – 1269
2025
Q1 		$299K Sell
46,089
-3,562
-7% -$31.7K 0.05% 673
2024
Q4 		$364K Buy
+49,651
New +$392K 0.07% 555
2024
Q3 		– Sell
-35,476
Closed -$316K – 1120
2024
Q2 		$316K Buy
35,476
+12,909
+57% +$124K 0.06% 543
2024
Q1 		$229K Buy
+22,567
New +$230K 0.05% 601

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's VIR Position: Q2 2025 in Review

Fox Run Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 46,089 shares — an estimated $299K sold.

Fox Run Management first reported a position in VIR in Q1 2024 and held it in 4 quarters. The position peaked at $364K in Q4 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Fox Run Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 46,089 Vir Biotechnology shares in Q2 2025, an estimated $299K.
  • Fox Run Management first reported a position in Vir Biotechnology in Q1 2024 and held it in 4 quarters.
  • Fox Run Management's Vir Biotechnology position peaked at $364K in Q4 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.